Loading clinical trials...
Loading clinical trials...
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Conditions
Interventions
ASTX295
Locations
11
United States
City of Hope Comprehensive Cancer Center Site#114
Duarte, California, United States
Cedars-Sinai Medical Center Site #105
Los Angeles, California, United States
Hoag Hospital Site#110
Newport Beach, California, United States
Holden Comprehensive Cancer Center Site#108
Iowa City, Iowa, United States
University of Michigan Rogel Cancer Center Site#109
Ann Arbor, Michigan, United States
Regions Cancer Center Site #115
Saint Paul, Minnesota, United States
Start Date
July 11, 2019
Primary Completion Date
September 11, 2023
Completion Date
August 15, 2024
Last Updated
April 9, 2025
NCT07489378
NCT07181681
NCT06257264
NCT07360314
NCT07204340
NCT03340506
Lead Sponsor
Taiho Oncology, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions